191 related articles for article (PubMed ID: 34533824)
1. Age-related prescription medication utilization for the -management of sickle cell disease among Texas Medicaid patients.
Shukla N; Barner JC; Lawson KA; Rascati KL
J Opioid Manag; 2021; 17(4):301-310. PubMed ID: 34533824
[TBL] [Abstract][Full Text] [Related]
2. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
3. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
[No Abstract] [Full Text] [Related]
4. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
[TBL] [Abstract][Full Text] [Related]
5. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
Su ZT; Segal JB; Lanzkron S; Ogunsile FJ
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
7. Daily home opioid use in adults with sickle cell disease: The PiSCES project.
Smith WR; McClish DK; Dahman BA; Levenson JL; Aisiku IP; de A Citero V; Bovbjerg VE; Roberts JD; Penberthy LT; Roseff SD
J Opioid Manag; 2015; 11(3):243-53. PubMed ID: 25985809
[TBL] [Abstract][Full Text] [Related]
8. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
10. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
[TBL] [Abstract][Full Text] [Related]
12. Opioid Prescription Filling Trends Among Children with Sickle Cell Disease After the Release of State-Issued Guidelines on Pain Management.
Creary SE; Chisolm DJ; Wrona SK; Cooper JN
Pain Med; 2020 Oct; 21(10):2583-2592. PubMed ID: 32142138
[TBL] [Abstract][Full Text] [Related]
13. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
[TBL] [Abstract][Full Text] [Related]
14. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M; Valle J; Paulukonis S; Holl JL; Tanabe P; French DD; Garg R; Liem RI; Badawy SM; Treadwell MJ
Pediatr Blood Cancer; 2020 May; 67(5):e28152. PubMed ID: 32147964
[TBL] [Abstract][Full Text] [Related]
15. Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines.
Reeves SL; Peng HK; Wing JJ; Cogan LW; Goel A; Anders D; Green NS; Lisabeth LD; Dombkowski KJ
JAMA Netw Open; 2023 Mar; 6(3):e234584. PubMed ID: 36961463
[TBL] [Abstract][Full Text] [Related]
16. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
17. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
[TBL] [Abstract][Full Text] [Related]
18. Opioid Use Among Children and Adults With Sickle Cell Disease in North Carolina Medicaid Enrollees in the Era of Opioid Harm Reduction.
Crego N; Douglas C; Bonnabeau E; Eason K; Earls M; Tanabe P; Shah N
J Pediatr Hematol Oncol; 2024 May; 46(4):181-187. PubMed ID: 38551912
[TBL] [Abstract][Full Text] [Related]
19. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
20. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]